Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention

Schizophrenia Research

Volumn 119, Issue 1-3, 2010, Pages 1-10

  Francey, S M ^b,c   Nelson, B ^a,b,c   Thompson, A ^a,b,c   Parker, A G ^a,c   Kerr, M ^a,c   Macneil, C ^b,c   Fraser, R ^b,c   Hughes, F ^b,c   Crisp, K ^b,c   Harrigan, S ^a,c   Wood, S J ^c   Berk, M ^a,b,c,d   McGorry, P D ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Antipsychotics; DUP; Early psychosis; Randomised controlled trial; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

AUDITORY HALLUCINATION; BIPOLAR DISORDER; COGNITIVE THERAPY; DISEASE COURSE; DRUG EFFICACY; EARLY DIAGNOSIS; GLUCOSE METABOLISM; HUMAN; INTERVENTION STUDY; LOW DRUG DOSE; MEDICAL ETHICS; MENTAL HEALTH SERVICE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOEDUCATION; PSYCHOSIS; PSYCHOSOCIAL CARE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BRAIN; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COUNSELING; DOSE-RESPONSE RELATIONSHIP, DRUG; EARLY DIAGNOSIS; ETHICS, MEDICAL; FAMILY THERAPY; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; SCHIZOPHRENIA; SOCIAL SUPPORT;

EID: 77952674645     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.02.1071     Document Type: Review

References (122)

1. Addington D., Addington J. First-episode psychosis. Clinical Handbook of Schizophrenia 2008, 367-379. Guildford Press, New York. K.T. Mueser, D.V. Jeste (Eds.).
2. Allison D.B., Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry 2001, 62(Suppl 7):22-31.
3. Alvarez-Jimenez M., Gonzalez-Blanch C., Crespo-Facorro B., Hetrick S., Rodriguez-Sanchez J.M., Perez-Iglesias R., et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008, 22(7):547-562.
4. Amminger, G. P., Schäfer, M., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., et al., 2010. Long-Chain Omega-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial. Archives of General Psychiatry 67 (2), 146-154.
5. Becker, H. E., Nieman, D. H., Wiltink, S., Dingemans, P. M., van de Fliert, J. R., Velthorst, E., et al. Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration? Psychol Med, 1-8.
6. Berger G.E., Wood S.J., Pantelis C., Velakoulis D., Wellard R.M., McGorry P.D. Implications of lipid biology for the pathogenesis of schizophrenia. Aust. NZ J. Psychiatry 2002, 36(3):355-366.
7. Berger G.E., Wood S., McGorry P.D. Incipient neurovulnerability and neuroprotection in early psychosis. Psychopharmacol. Bull. 2003, 37(2):79-101.
8. Berger G.E., Wood S.J., Ross M., Yung A.R., Nelson B., Hamer C., et al. Neuroprotective effects of low dose lithium in individuals at ultra-high risk for psychosis. Early Interv. Psychiatry 2008, 2(1):A28.
9. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int. J. Neuropsychopharmacol. 2009, 12(4):441-445.
10. Berk, M., and Parker, G., 2009. The elephant on the couch: side effects of psychotherapy. Aust N Z J Psychiatry 43 (9), 787-794.
11. Berk M., Hallam K.T., McGorry P.D. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J. Affect Disord. 2007, 100(1-3):279-281.
12. Berk M., Copolov D., Dean O., Lu K., Jeavons S., Schapkaitz I., et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry 2008, 64(5):361-368.
13. Berk M., Ng F., Dean O., Dodd S., Bush A.I. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol. Sci. 2008, 29(7):346-351.
14. Bertelsen M., Jeppesen P., Petersen L., Thorup A., Ohlenschlaeger J., le Quach P., et al. Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Arch. Gen. Psychiatry 2008, 65(7):762-771.
15. Birchwood M. Early intervention and sustaining the management of vulnerability. Aust. NZ J. Psychiatry 2000, 34:S181-184. Suppl.
16. Bola J.R. Medication-free research in early episode schizophrenia: evidence of long-term harm?. Schizophr. Bull. 2006, 32(2):288-296.
17. Bola J.R. Psychosocial acute treatment in early-epsiode schizophrenia disorders. Res. Soc. Work Pract. 2006, 16:263-275.
18. Bola J.R., Mosher L.R. Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project. J. Nerv. Ment. Dis. 2003, 191(4):219-229.
19. Bola J.R., Lehtinen K., Aaltonen J., Rakkolainen V., Syvalahti E., Lehtinen V. Predicting medication-free treatment response in acute psychosis: cross-validation from the Finnish Need-Adapted Project. J. Nerv. Ment. Dis. 2006, 194(10):732-739.
20. Bola J.R., Lehtinen K., Cullberg J., Ciompi L. Psychosocial treatment, antipsychotic postponement, and low-dose medication strategies in first-episode psychosis: a review of the literature. Psychosis: Psychol. Soc. Integr. Approaches. 2009, 1(1):4-18.
21. Brewer W.J., Francey S.M., Wood S.J., Jackson H.J., Pantelis C., Phillips L.J., et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am. J. Psychiatry 2005, 162(1):71-78.
22. Brewer W.J., Wood S.J., Phillips L.J., Francey S.M., Pantelis C., Yung A.R., et al. Generalised and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophr. Bull. 2006, 32:538-555.
23. Carbone S., Harrigan S., McGorry P.D., Curry C., Elkins K. Duration of untreated psychosis and 12-month outcome in first-episode psychosis: the impact of treatment approach. Acta Psychiatr. Scand. 1999, 100(2):96-104.
24. Carpenter W.T. The risk of medication-free research. Schizophr. Bull. 1997, 23(1):11-18.
25. Carpenter W.T., Appelbaum P.S., Levine R.J. The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. Am. J. Psychiatry 2003, 160(2):356-362.
26. Coldham E.L., Addington J., Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr. Scand. 2002, 106(4):286-290.
27. Corson P.W., Nopoulos P., Miller D.D., Arndt S., Andreasen N.C. Change in basal ganglia volume over 2years in patients with schizophrenia: typical versus atypical neuroleptics. Am. J. Psychiatry 1999, 156(8):1200-1204.
28. Crow T.J., MacMillan J.F., Johnson A.J., Johnstone E.C. The Northwick study of first episodes of schizophrenia. Br. J. Psychiatry 1986, 148:120-127.
29. DeLisi L.E. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr. Bull. 2008, 34(2):312-321.
30. Dorph-Petersen K.A., Pierri J.N., Perel J.M., Sun Z., Sampson A.R., Lewis D.A. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacol. 2005, 30(9):1649-1661.
31. Edwards J., McGorry P.D. Implementing Early Intervention in Psychosis: A Guide to Establishing Early Psychosis Services 2002, Dunitz, London.
32. Edwards J., Elkins K., Hinton M., Harrigan S.M., Donovan K., Athanasopoulos O., et al. Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatr. Scand. 2006, 114(2):109-117.
33. EPPIC Case Management in Early Psychosis: A Handbook. Melbourne: Early Psychosis Prevention and Intervention Centre 2001.
34. Fava G.A., Kellner R. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr. Scand. 1993, 87:225-230.
35. Gardner D.M., Baldessarini R.J., Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005, 172(13):1703-1711.
36. Garety P.A., Freeman D. Cognitive approaches to delusions: a critical review of theories and evidence. Br. J. Clin. Psychol. 1999, 38:113-154.
37. Garety P.A., Fowler D., Kuipers E. Cognitive-behavioral therapy for medication-resistant symptoms. Schizophr. Bull. 2000, 26(1):73-86.
38. Gleeson J.F., Cotton S.M., Alvarez-Jimenez M., Wade D., Gee D., Crisp K., et al. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. J. Clin. Psychiatry 2009, 70(4):477-486.
39. Group I.E.P.A.W. International clinical practice guidelines for early psychosis. Br. J. Psychiatry 2005, 187(Supplement 48):s120-s124.
40. Haddock G., Lewis S. Psychological interventions in early psychosis. Schizophr. Bull. 2005, 31(3):697-704.
41. Harrigan S.M., McGorry P.D., Krstev H. Does treatment delay in first-episode psychosis really matter?. Psychol. Med. 2003, 33(1):97-110.
42. Hetrick S.E., Parker A.G., Hickie I.B., Purcell R., Yung A.R., McGorry P.D. Early identification and intervention in depressive disorders: towards a clinical staging model. Psychother. Psychosom. 2008, 77(5):263-270.
43. Jackson H., McGorry P., Henry L., Edwards J., Hulbert C., Harrigan S., et al. Cognitively oriented psychotherapy for early psychosis (COPE): a 1-year follow-up. Br. J. Clin. Psychol. 2001, 40(Pt 1):57-70.
44. Jackson H., McGorry P., Edwards J., Hulbert C., Henry L., Harrigan S., et al. A controlled trial of cognitively oriented psychotherapy for early psychosis (COPE) with four-year follow-up readmission data. Psychol. Med. 2005, 35(9):1295-1306.
45. Jackson H.J., McGorry P.D., Killackey E., Bendall S., Allott K., Dudgeon P., et al. Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus befriending for first-episode psychosis: the ACE project. Psychol. Med. 2008, 38(5):725-735.
46. Job D.E., Whalley H., Johnstone E.C., Lawrie S.M. Grey matter changes over time in high risk subjects developing schizophrenia. NeuroImage 2005, 25:1023-1030.
47. Johannessen J.O., McGlashan T.H., Larsen T.K., Horneland M., Joa I., Mardal S., et al. Early detection strategies for untreated first-episode psychosis. Schizophr. Res. 2001, 51(1):39-46.
48. Johannessen J.O., Larsen T.K., Joa I., Melle I., Friis S., Opjordsmoen S., et al. Pathways to care for first-episode psychosis in an early detection healthcare sector: part of the Scandinavian TIPS study. Br. J. Psychiatry Suppl. 2005, 48:s24-28.
49. Johns L.C., van Os J. The continuity of psychotic experiences in the general population. Clin. Psychol. Rev. 2001, 21(8):1125-1141.
50. Johnstone E.C., Owens D.G., Crow T.J., Davis J.M. Does a four-week delay in the introduction of medication alter the course of functional psychosis?. J. Psychopharmacol. 1999, 13(3):238-244.
51. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371(9618):1085-1097.
52. Kane J.M., Malhotra A. The future of pharmacotherapy for schizophrenia. World Psychiatry 2003, 2(2):81-86.
53. Keshavan M.S., Amirsadri A. Early intervention in schizophrenia: current and future perspectives. Curr. Psychiatry Rep. 2007, 9(4):325-328.
54. Killackey E., Yung A.R. Effectiveness of early intervention in psychosis. Curr. Opin. Psychiatry 2007, 20(2):121-125.
55. Killackey E., Jackson H.J., McGorry P.D. Vocational intervention in first-episode psychosis: individual placement and support v. treatment as usual. Br. J. Psychiatry 2008, 193(2):114-120.
56. Konopaske G.T., Dorph-Petersen K.A., Pierri J.N., Wu Q., Sampson A.R., Lewis D.A. Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacol. 2007, 32(6):1216-1223.
57. Lambert T.J., Chapman L.H. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med. J. Aust. 2004, 181(10):544-548.
58. Larsen T.K., Melle I., Auestad B., Friis S., Haahr U., Johannessen J.O., et al. Early detection of first-episode psychosis: the effect on 1-year outcome. Schizophr. Bull. 2006, 32(4):758-764.
59. Laurens K.R., Hodgins S., Maughan B., Murray R.M., Rutter M.L., Taylor E.A. Community screening for psychotic-like experiences and other putative antecedents of schizophrenia in children aged 9-12years. Schizophr. Res. 2007, 90(1-3):130-146.
60. Le Grange D., Loeb K.L. Early identification and treatment of eating disorders: prodrome to syndrome. Early Intervent. in Psychiatry 2007, 1:27-39.
61. Lehtinen V., Aaltonen J., Koffert T., Rakkolainen V., Syvalahti E. Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed?. Eur. Psychiatry 2000, 15(5):312-320.
62. Lenior M.E., Dingemans P.M., Linszen D.H., de Haan L., Schene A.H. Social functioning and the course of early-onset schizophrenia: five-year follow-up of a psychosocial intervention. Br. J. Psychiatry 2001, 179:53-58.
63. Lewis S., Tarrier N., Haddock G., Bentall R., Kinderman P., Kingdon D., et al. Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. Br. J. Psychiatry 2002, 181(Suppl 43):s91-s97.
64. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
65. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 2005, 62(4):361-370.
66. Linszen D., Lenoir M., De Haan L., Dingemans P., Gersons B. Early intervention, untreated psychosis and the course of recent onset schizophrenia. Br. J. Psychiatry 1998, 172(Suppl 33):84-89.
67. Llorca P.M., Chereau I., Bayle F.J., Lancon C. Tardive dyskinesias and antipsychotics: a review. Eur. Psychiatry 2002, 17(3):129-138.
68. Loebel A.D., Lieberman J.A., Alvir J.M., Mayerhoff D.I., Geisler S.H., Szymanski S.R. Duration of psychosis and outcome in first-episode schizophrenia. Am. J. Psychiatry 1992, 149(9):1183-1188.
69. Macneil C.A., Hasty M.K., Redlich C., Berk M. The therapeutic alliance: is it necessary or sufficient to engender positive outcomes?. Acta Neuropsychiatrica 2009, 2:95-98.
70. Malla A.K., Norman R.M., Joober R. First-episode psychosis, early intervention, and outcome: what have we learned?. Can. J. Psychiatry 2005, 50(14):881-891.
71. Marshall M., Lewis S., Lockwood A., Drake R., Jones P., Croudace T. Association between duration of untreated psychosis and in cohorts of first-episode outcome patients - a systematic review. Arch. Gen. Psychiatry 2005, 62(9):975-983.
72. McGlashan T.H. Early detection and intervention of schizophrenia: rationale and research. Br. J. Psychiatry 1998, 172(Suppl 33):3-6.
73. McGlashan T.H. Rationale and parameters for medication-free research in psychosis. Schizophr. Bull. 2006, 32(2):300-302.
74. McGlashan T., Johannessen J. Early detection and intervention with schizophrenia: rationale. Schizophr. Bull. 1996, 22:201-222.
75. McGorry P.D. Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. Am. J. Psychiatry 2007, 164(6):859-860.
76. McGorry P.D. The specialist youth mental health model: strengthening the weakest link in the public mental health system. Med. J. Aust. 2007, 187(7 Suppl):S53-56.
77. McGorry P.D., Yung A.R. Early intervention in psychosis: an overdue reform. Aust. NZ. J. Psychiatry 2003, 37:393-398.
78. McGorry P.D., Edwards J., Mihalopoulos C., Harrigan S., Jackson H. EPPIC - an evolving system of early detection and optimal management. Schizophr. Bull. 1996, 22:305-326.
79. McGorry P.D., Hickie I.B., Yung A.R., Pantelis C., Jackson H.J. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust. NZ J. Psychiatry 2006, vol 40(8):616-622. Aug 2006.
80. McGorry P.D., Killackey E., Yung A.R. Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages. Med. J. Aust. 2007, 187(7 Suppl):S8-10.
81. McGorry P.D., Purcell R., Hickie I.B., Yung A.R., Pantelis C., Jackson H.J. Clinical staging: a heuristic model for psychiatry and youth mental health. Med. J. Aust. 2007, 187(7):S40-S42.
82. McGorry P.D., Killackey E., Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry 2008, 7(3):148-156.
83. McNulty J. Medication-free research in early episode schizophrenia: why on earth would I choose to participate in such research?. Schizophr. Bull. 2006, 32(2):305-306.
84. Melle I., Larsen T.K., Haahr U., Friis S., Johannessen J.O., Opjordsmoen S., et al. Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch. Gen. Psychiatry 2004, 61(2):143-150.
85. Melle I., Johannesen J.O., Friis S., Haahr U., Joa I., Larsen T.K., et al. Early detection of the first episode of schizophrenia and suicidal behavior. Am. J. Psychiatry 2006, 163(5):800-804.
86. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65(9):732-741.
87. Morrison A.P. The interpretation of intrusions in psychosis: an integrative cognitive approach to hallucinations and delusions. Behav. and Cogn. Psychother. 2001, 29:257-276.
88. A Casebook of Cognitive Therapy for Psychosis 2002, Brunner-Routledge, New York. A.P. Morrison (Ed.).
89. Muench J., Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J. Am. Board Fam. Pract. 2001, 14(4):278-282.
90. Nakamura M., Salisbury D.F., Hirayasu Y., Bouix S., Pohl K.M., Yoshida T., et al. Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study. Biol. Psychiatry 2007, 62(7):773-783.
91. Nordentoft M., Jeppesen P., Abel M., Kassow P., Petersen L., Thorup A., et al. OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis: one-year follow-up of a randomised controlled trial. Br. J. Psychiatry 2002, 181(Suppl 43):s98-s106.
92. Oehl M., Hummer M., Fleischhacker W.W. Compliance with antipsychotic treatment. Acta Psychiatr. Scand. Suppl. 2000, 407:83-86.
93. Pantelis C., Yücel M., Wood S.J., McGorry P.D., Velakoulis D. Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Aust. NZ J. Psychiatry 2003, 37:399-406.
94. Penn D.L., Waldheter E.J., Perkins D.O., Mueser K.T., Lieberman J.A. Psychosocial treatment for first-episode psychosis: a research update. Am. J. Psychiatry 2005, 162(12):2220-2232.
95. Perkins D.O. Adherence to antipsychotic medications. J. Clin. Psychiatry 1999, 60(Suppl 21):25-30.
96. Perkins D.O., Gu H., Boteva K., Lieberman J.A. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry 2005, 162(10):1785-1804.
97. Poulton R., Caspi A., Moffitt T.E., Cannon M., Murray R.M., Harrington H. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch. Gen. Psychiatry 2000, 57:1053-1058.
98. Power P.J.R., Bell R., Mills R., Al E. Suicide prevention in first episode psychosis: the development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. Aust. NZ J. Psychiatry 2003, 37:414-420.
99. Riecher-Rossler A., Pflueger M.O., Aston J., Borgwardt S.J., Brewer W.J., Gschwandtner U., et al. Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. Biol. Psychiatry 2009, 66(11):1023-1030.
100. Rosen J.L., Miller T.J., D'Andrea J.T., McGlashan T.H., Woods S.W. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr. Res. 2006, vol 85(1-3):124-131. Jul 2006.
101. Sachs G.S., Thase M.E., Otto M.W., Bauer M., Miklowitz D., Wisniewski S.R., et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol. Psychiatry 2003, 53(11):1028-1042.
102. Schimmelmann B.G., Huber C.G., Lambert M., Cotton S., McGorry P.D., Conus P. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J. Psychiatry Res. 2008, 42(12):982-990.
103. Schooler N.R. Implications for future research of "medication-free research in early episode schizophrenia". Schizophr. Bull. 2006, 32(2):297-298.
104. Scott J., Paykel E., Morriss R., Bentall R., Kinderman P., Johnson T., et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br. J. Psychiatry 2006, 188:313-320.
105. Singh S.P., Burns T., Amin S., Jones P.B., Harrison G. Acute and transient psychotic disorders: precursors, epidemiology, course and outcome. Br. J. Psychiatry 2004, 185:452-459.
106. Stahl S.M., Mignon L., Meyer J.M. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?. Acta Psychiatr. Scand. 2009, 119(3):171-179.
107. Subramaniam M., Pek E., Verma S., Chan Y.H., Chong S.A. Diagnostic stability 2years after treatment initiation in the Early Psychosis Intervention Programme in Singapore. Aust. NZ J. Psychiatry 2007, 41(6):495-500.
108. Szymanski S.R., Cannon T.D., Gallacher F., Erwin R.J., Gurr R.E. Course of treatment response in first episode and chronic schizophrenia. Am. J. Psychiatry 1996, 153:519-525.
109. Takahashi T., Malhi G.S., Wood S.J., Walterfang M., Yucel M., Lorenzetti V., et al. Increased pituitary volume in patients with established bipolar affective disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(7):1245-1249.
110. Tarrier N. Cognitive behaviour therapy for schizophrenia - a review of development, evidence and implementation. Psychother. Psychosom. 2005, 74:136-144.
111. Tarrier N., Lewis S., Haddock G., Bentall R., Drake R., Kinderman P., et al. Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial. Br. J. Psychiatry 2004, 184:231-239.
112. Thompson P.M., Vidal C., Giedd J.N., Gochman P., Blumenthal J., Nicolson R., et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc. Natl. Acad. Sci. 2001, 98(20):11,650-11,655.
113. Tschoner A., Eng J., Laimer M., Kaser S., Rettenbacher M., Fleischhacker W.W., et al. Metabolic side effects of antipsychotic medication. Int. J. Clin. Pract. 2007, 61(8):1356-1370.
114. van der Heijden F.M., Tuinier S., Arts N.J., Hoogendoorn M.L., Kahn R.S., Verhoeven W.M. Catatonia: disappeared or under-diagnosed?. Psychopathol. 2005, 38(1):3-8.
115. van Os J., Hanssen M., Bijl R.V., Ravelli A. Straus (1969) revisited: a psychosis continuum in the general population?. Schizophr. Res. 2000, 45(1-2):11-20.
116. Velakoulis D., Wood S.J., Wong M.T., McGorry P.D., Yung A., Phillips L., et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch. Gen. Psychiatry 2006, 63(2):139-149.
117. Warden D., Rush A.J., Trivedi M.H., Fava M., Wisniewski S.R. The STARD Project results: a comprehensive review of findings. Curr. Psychiatry Rep. 2007, 9(6):449-459.
118. Whitty P., Clarke M., McTigue O., Browne S., Kamali M., Larkin C., et al. Diagnostic stability four years after a first episode of psychosis. Psychiatr. Serv. 2005, 56(9):1084-1088.
119. Wood S.J., Brewer W.J., Koutsouradis P., Phillips L.J., Francey S.M., Proffitt T.M., et al. Cognitive decline following psychosis onset: data from the PACE clinic. Br. J. Psychiatry Suppl. 2007, 51:s52-57.
120. Yung A.R., Buckby J.A., Cotton S.M., Cosgrave E.M., Killackey E.J., Stanford C., et al. Psychotic-like experiences in nonpsychotic help-seekers: associations with distress, depression, and disability. Schizophr. Bull. 2006, 32(2):352-359.
121. Yung A.R., Yuen H.P., Berger G., Francey S., Hung T.C., Nelson B., et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?. Schizophr. Bull. 2007, 33(3):673-681.
122. Yung A.R., Nelson B., Baker K., Buckby J.A., Baksheev G., Cosgrave E.M. Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia. Aust. NZ J. Psychiatry 2009, 43(2):118-128.